Helix BioPharma Reports Issuance of U.S. Patent for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47
Complete the form below to unlock access to ALL audio articles.
Helix BioPharma Corp., has announced the issuance of a patent (U.S. Patent No. 7,872,105 B2) by the United States Patent & Trademark Office for the non-small cell lung cancer-specific antibody component of its L-DOS47 drug candidate. As previously announced, the National Research Council of Canada ("NRC") has granted Helix the right to use this antibody in combination with its DOS47 technology under a worldwide exclusive license agreement that extends to the full term of the applicable patents.
L-DOS47 is the Company's first therapeutic immunoconjugate drug candidate under development based upon its novel DOS47 technology, which is designed to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction. L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic NSCLC.
L-DOS47 combines Helix's DOS47 technology with NRC's highly specialized camelid-derived single domain antibody, which is designed to identify a unique CEACAM6 antigenic site predominantly associated with NSCLC cells.
"We congratulate the NRC," said Donald Segal Ph.D., Chairman & CEO of Helix. "This patent protects the antibody entity that is used to construct L-DOS47, and in turn adds significant strength to L-DOS47's patent protection."
Helix recently announced on February 7th, 2011 that it had received approval from the U.S. Food and Drug Administration to conduct a U.S. Phase I clinical study with L-DOS47. Helix also recently announced on February 24th, 2011 that it had filed a European clinical trial application seeking regulatory approval to also conduct a Phase I/II clinical study with L-DOS47.
